Is LMP Capital and Income Fund Inc. (SCD) a Buy, Sell, or Hold?
NYSE : SCD
LMP Capital and Income Fund Inc.
$15.3 USD
-$0.14 (-0.91%)
- Volume
- 156.76K
- Average Volume
- 64.95K
- Market Capitalization
- $5.13B
- P/E Ratio
- -31.22
- Dividend Yield
- 9.41%
- Price Target
- Year High
- $16.18
- Year Low
- $13.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$32.78
- Current Ratio
- $0.28
| Source | Headline |
|---|---|
|
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle. Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025. prnewswire.com - 2026-07-16 07:30:00 |
|
10 Best CEFs This Month: Average Yield Of Near 10% (June 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.8% plus yield and nearly 7.5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. seekingalpha.com - 2026-06-27 08:15:00 |
|
SCD: Gets The Job Done But Not The Most Efficient Income Fund
LMP Capital and Income Fund maintains a 9.2% yield, with management expressing confidence in sustaining current distributions through August. Recent performance and distribution consistency have been concerns, leading to a hold rating on SCD. Franklin Templeton's management strategy and risk profile are key considerations for SCD's forward outlook. seekingalpha.com - 2026-06-18 02:42:46 |
|
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5--11, at the European Hematology Association Congress and Announces Additional Global Regulatory Su
[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVYÂ (exagamglogene autotemcel gurufocus.com - 2026-06-11 03:00:00 |
|
10 Best CEFs This Month: Average Yield Of 9% Plus (May 2026)
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9% plus yield and nearly 7.5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. seekingalpha.com - 2026-05-23 08:30:00 |
|
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its gurufocus.com - 2026-05-15 16:00:00 |
